Get the Stockscreener App
23.82
5.87%
1.32
Pre-market:
26.99
3.17
+13.31%
Lenz Therapeutics Inc stock is traded at $23.82, with a volume of 141.15K.
It is up +5.87% in the last 24 hours and down -27.00% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$22.50
Open:
$22.62
24h Volume:
141.15K
Relative Volume:
0.87
Market Cap:
$655.07M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-4.2556
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
+6.53%
1M Performance:
-27.00%
6M Performance:
+11.05%
1Y Performance:
+0.00%
1-Day Range:
$22.62
$24.29
1-Week Range:
$21.34
$24.29
52-Week Range:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
23.82 | 655.07M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) Short Interest Down 5.0% in December - Defense World
LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Sees Significant Increase in Short Interest - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Sees Significant Increase in Short Interest - Defense World
Morgan Stanley Cuts U.S. Bancorp (NYSE:USB) Price Target to $59.00 - Defense World
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 11.9% - MarketBeat
Barclays PLC Has $391,000 Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Barclays PLC Buys 12,051 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5%Time to Sell? - MarketBeat
Harbor Capital Advisors Inc. Buys Shares of 43,989 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Jane Street Group LLC Acquires Shares of 12,027 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.9%Here's What Happened - MarketBeat
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Lenz Therapeutics New Becomes Oversold (LENZ) - Nasdaq
Financial Survey: Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Buy" from Brokerages - MarketBeat
SkyWater Technology, Inc. (NASDAQ:SKYT) Shares Purchased by Barclays PLC - Defense World
NI Holdings, Inc. (NASDAQ:NODK) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Raises Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.1%What's Next? - MarketBeat
State Street Corp Raises Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by State Street Corp - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 6.3%Should You Buy? - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1% – What’s Next? - Defense World
Wellington Management Group LLP Invests $585,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1%Time to Sell? - MarketBeat
BNP Paribas Financial Markets Has $63,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Presbyopia Therapeutics Market Size was highest in the US among the 7MM, was ~USD 8,039 million, and is expected to increase by 2034 | DelveInsight - Barchart
Presbyopia Therapeutics Market Size was highest in the US among - openPR
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 5.8%Here's What Happened - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40 - Defense World
Charles Schwab Investment Management Inc. Has $2.93 Million Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Charles Schwab Investment Management Inc. Has $2.93 Million Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Sotherly Hotels (NASDAQ:SOHOO) Shares Down 5% – Here’s What Happened - Defense World
XOMA (NASDAQ:XOMAP) Trading Down 0.6% – Should You Sell? - Defense World
Onfolio (NASDAQ:ONFO) Trading 1.1% Higher – Should You Buy? - Defense World
Sumco (OTCMKTS:SUMCF) Shares Up 2.4% – Still a Buy? - Defense World
Cizzle Biotechnology (LON:CIZ) Shares Down 5% – What’s Next? - Defense World
NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World
Glass House Brands (OTCMKTS:GLASF) Shares Up 1.3% – Here’s What Happened - Defense World
The Manufacturers Life Insurance Company Has $740,000 Stock Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Century Lithium (CVE:LCE) Trading Down 1.7% – Here’s What Happened - Defense World
Shaftesbury Capital (LON:SHC) Trading Down 1.4% – Here’s What Happened - Defense World
Short Interest in DatChat, Inc. (NASDAQ:DATS) Drops By 56.0% - Defense World
Metal Sky Star Acquisition (NASDAQ:MSSAU) Trading 1.6% Higher – Should You Buy? - Defense World
Indaptus Therapeutics (NASDAQ:INDP) Shares Down 1% – Here’s Why - Defense World
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):